15.14.02 · orgchem / enzyme-mechanism

Enzyme kinetics beyond Michaelis-Menten: inhibition, allosteric enzymes, and Hill coefficients

stub3 tiersLean: nonepending prereqs

Anchor (Master): Segel — Enzyme Kinetics (Wiley, 1993)

Intuition Beginner

The Michaelis-Menten equation describes the simplest enzymes: one substrate, one active site, no regulation. Real enzymes are more complicated. Molecules called inhibitors bind to enzymes and slow them down. Some inhibitors compete with the substrate for the active site. Others bind at a different location and change the enzyme's shape. Understanding inhibition is essential for pharmacology — most drugs are enzyme inhibitors.

Allosteric enzymes break the Michaelis-Menten rules entirely. They have multiple subunits, and when substrate binds to one subunit, it changes the affinity of the other subunits. This is called cooperativity. The result is a sigmoidal (S-shaped) rate curve instead of the hyperbolic Michaelis-Menten curve. Hemoglobin is the classic example: binding the first oxygen molecule makes it easier for the remaining subunits to bind oxygen.

The Hill coefficient ( $n_{H}$ ) measures cooperativity quantitatively. When $n_{H} = 1$ , there is no cooperativity (Michaelis-Menten behaviour). When $n_{H} > 1$ , the enzyme shows positive cooperativity — each substrate molecule that binds makes the next one bind more easily. When $n_{H} < 1$ , the enzyme shows negative cooperativity — each substrate molecule makes the next one harder to bind.

Visual Beginner

The three main types of reversible inhibition affect the Michaelis-Menten graph differently. A competitive inhibitor raises the apparent $K_{M}$ but leaves $V_{ma x}$ unchanged — on a Lineweaver-Burk plot, lines intersect on the y-axis. An uncompetitive inhibitor lowers both $K_{M}$ and $V_{ma x}$ equally — lines are parallel. A mixed inhibitor lowers $V_{ma x}$ and changes $K_{M}$ — lines intersect to the left of the y-axis.

For allosteric enzymes, the rate curve is S-shaped rather than hyperbolic. Steeper sigmoidal curves correspond to higher Hill coefficients and stronger cooperativity.

Worked example Beginner

Identifying inhibition type from kinetic data.

An enzyme has $K_{M} = 2.0 mM$ and $V_{ma x} = 100 μ M/min$ without inhibitor. In the presence of a $5 mM$ inhibitor, the apparent $K_{M}$ increases to $6.0 mM$ but $V_{ma x}$ stays at $100 μ M/min$ .

Step 1: Check $V_{ma x}$ . Unchanged — this rules out uncompetitive and mixed inhibition, both of which change $V_{ma x}$ .

Step 2: Check $K_{M}$ . Increased — the inhibitor makes the enzyme appear to have lower affinity for the substrate.

Step 3: Conclusion. The inhibitor is competitive. It binds the free enzyme at the active site, competing with substrate. Adding more substrate overcomes the inhibition, so $V_{ma x}$ is unaffected but the apparent $K_{M}$ increases by a factor of $1 + [I] / K_{I}$ . Here, $1 + [I] / K_{I} = 6.0/2.0 = 3$ , so $K_{I} = 5.0/2 = 2.5 mM$ .

Check your understanding Beginner

Formal definition Intermediate+

Reversible inhibition kinetics. The standard Michaelis-Menten mechanism is extended by introducing inhibitor binding equilibria. Three canonical types are distinguished by where the inhibitor binds and how it affects the kinetic parameters.

Competitive inhibition. The inhibitor I binds the free enzyme E at the active site, competing with substrate S. Mechanism: $E + I ⇌ EI$ (inactive), with dissociation constant $K_{I} = [E] [I] / [E I]$ . The rate equation becomes:

v = \frac{V _{ma x} [ S ]}{K _{M} ( 1 + [ I ] / K _{I} ) + [ S ]}

The apparent Michaelis constant is $K_{M}^{a pp} = K_{M} (1 + [I] / K_{I})$ ; $V_{ma x}$ is unchanged. On a Lineweaver-Burk plot ( $1/ v$ vs $1/ [S]$ ), the slope $K_{M} / V_{ma x}$ increases but the y-intercept $1/ V_{ma x}$ is constant — lines intersect on the y-axis.

Uncompetitive inhibition. The inhibitor binds only the ES complex. Mechanism: $ES + I ⇌ ESI$ (inactive), with $K_{I}^{'} = [E S] [I] / [E S I]$ . The rate equation:

v = \frac{V _{ma x} [ S ] / ( 1 + [ I ] / K _{I}^{'} )}{K _{M} / ( 1 + [ I ] / K _{I}^{'} ) + [ S ]}

Both $V_{ma x}^{a pp} = V_{ma x} / (1 + [I] / K_{I}^{'})$ and $K_{M}^{a pp} = K_{M} / (1 + [I] / K_{I}^{'})$ decrease by the same factor. On a Lineweaver-Burk plot, the slope $K_{M} / V_{ma x}$ is constant — parallel lines.

Mixed inhibition. The inhibitor binds both E and ES with different affinities ( $K_{I}$ for E, $K_{I}^{'}$ for ES). The rate equation:

v = \frac{V _{ma x} [ S ] / ( 1 + [ I ] / K _{I}^{'} )}{K _{M} ( 1 + [ I ] / K _{I} ) / ( 1 + [ I ] / K _{I}^{'} ) + [ S ]}

$V_{ma x}$ always decreases. $K_{M}$ increases if $K_{I} < K_{I}^{'}$ (inhibitor prefers free E), decreases if $K_{I} > K_{I}^{'}$ (inhibitor prefers ES), or is unchanged if $K_{I} = K_{I}^{'}$ . The special case $K_{I} = K_{I}^{'}$ is noncompetitive inhibition: $V_{ma x}^{a pp} = V_{ma x} / (1 + [I] / K_{I})$ and $K_{M}^{a pp} = K_{M}$ .

On a Lineweaver-Burk plot for mixed inhibition, lines intersect to the left of the y-axis (above or below the x-axis depending on whether $K_{I} < K_{I}^{'}$ or $K_{I} > K_{I}^{'}$ ). For pure noncompetitive inhibition, lines intersect on the x-axis.

Determining $K_{I}$ from kinetic data. The inhibitor constant $K_{I}$ is extracted from replots. For competitive inhibition, the slope of the Lineweaver-Burk plot ( $K_{M} / V_{ma x}$ ) varies linearly with $[I]$ : slope $= (K_{M} / V_{ma x}) (1 + [I] / K_{I})$ . A plot of slope vs $[I]$ is linear with x-intercept $= - K_{I}$ . For noncompetitive inhibition, $1/ V_{ma x}^{a pp}$ varies linearly with $[I]$ , and the x-intercept gives $- K_{I}$ . Dixon plots ( $1/ v$ vs $[I]$ at fixed $[S]$ ) provide an alternative graphical method.

The Hill equation and cooperativity. For enzymes with cooperative substrate binding, the Hill equation replaces Michaelis-Menten:

v = \frac{V _{ma x} [ S ] ^{n_{H}}}{K _{0.5}^{n_{H}} + [ S ] ^{n_{H}}}

where $n_{H}$ is the Hill coefficient and $K_{0.5}$ is the substrate concentration at half-maximal velocity. The Hill equation is empirical — it describes the data well but does not correspond to a unique physical mechanism. It is derived by assuming that the enzyme has $n$ substrate binding sites that are either all empty or all occupied simultaneously (a nonphysical assumption used as a curve-fitting tool). Taking logarithms:

lo g (\frac{v}{V _{ma x} - v}) = n_{H} lo g [S] - n_{H} lo g K_{0.5}

A plot of $lo g (v / (V_{ma x} - v))$ vs $lo g [S]$ (the Hill plot) is linear in the midrange with slope $n_{H}$ . The Hill coefficient is always less than or equal to the number of binding sites $n$ , with $n_{H} < n$ indicating that the cooperative transition is not infinitely sharp.

Counterexamples to common slips

"Competitive inhibitors always bind the active site." Competitive inhibition is defined kinetically (increased $K_{M}$ , unchanged $V_{ma x}$ ), not structurally. A molecule binding at a distant site that prevents substrate binding through a conformational change also produces competitive kinetics. The kinetic type does not uniquely determine the binding location.
"Noncompetitive and mixed inhibition are the same." Noncompetitive inhibition is the special case of mixed inhibition where $K_{I} = K_{I}^{'}$ . Mixed inhibition with $K_{I} \neq = K_{I}^{'}$ changes both $V_{ma x}$ and $K_{M}$ , while pure noncompetitive inhibition changes only $V_{ma x}$ .
"The Hill coefficient equals the number of binding sites." The Hill coefficient $n_{H}$ is always less than or equal to $n$ (the number of sites) and measures the degree of cooperativity, not the number of sites. For hemoglobin ( $n = 4$ ), $n_{H} \approx 2.8$ , not 4.
"Allosteric enzymes always show sigmoidal kinetics." An allosteric enzyme in the R state (high-affinity conformation) shows near-hyperbolic kinetics. Sigmoidicity requires a population shift between T and R states as substrate concentration changes. If $L = [T_{0}] / [R_{0}]$ is small (R state favoured), the curve is nearly hyperbolic.

Key mechanism Intermediate+

Lineweaver-Burk, Eadie-Hofstee, and Hanes-Woolf linearization. Before computational nonlinear regression was routine, enzyme kineticists used linear transformations of the Michaelis-Menten equation to extract $K_{M}$ and $V_{ma x}$ from experimental data. Each method has characteristic error-distribution properties.

The Lineweaver-Burk plot (double-reciprocal, $1/ v$ vs $1/ [S]$ ):

\frac{1}{v} = \frac{K _{M}}{V _{ma x}} \cdot \frac{1}{[ S ]} + \frac{1}{V _{ma x}}

This is the most common but also the most error-prone linearization. Points at low $[S]$ (high $1/ [S]$ ) are heavily weighted, amplifying measurement error. It is nevertheless the standard for diagnosing inhibition type because the three canonical patterns (y-axis intersection, parallel lines, left-axis intersection) are visually distinctive.

The Eadie-Hofstee plot ( $v$ vs $v / [S]$ ):

v = V_{ma x} - K_{M} \cdot \frac{v}{[ S ]}

This avoids the problem of compressing high- $[S]$ data into a small region. However, $v$ appears on both axes, so experimental error in $v$ distorts the regression in both dimensions. It is more robust than Lineweaver-Burk for estimating $K_{M}$ but less useful for inhibition diagnostics.

The Hanes-Woolf plot ( $[S] / v$ vs $[S]$ ):

\frac{[ S ]}{v} = \frac{1}{V _{ma x}} \cdot [S] + \frac{K _{M}}{V _{ma x}}

This provides the most statistically balanced weighting of data points and is preferred when the goal is accurate parameter estimation rather than visual inhibition diagnosis.

Modern practice uses nonlinear least-squares regression to fit the Michaelis-Menten (or Hill) equation directly, but the linearization plots remain indispensable for diagnosing inhibition mechanisms because the visual patterns (intersection geometry on the Lineweaver-Burk plot) are far more informative than a list of fitted parameters.

Allosteric models: the MWC concerted framework. The Monod-Wyman-Changeux (MWC) model describes allosteric enzymes as oligomers existing in two conformational states: the T state (tense, low affinity) and the R state (relaxed, high affinity). The allosteric constant $L = [T_{0}] / [R_{0}]$ describes the equilibrium between unliganded conformations. Each ligand binds R with microscopic dissociation constant $K_{R}$ and T with $K_{T} = c \cdot K_{R}$ , where $c = K_{T} / K_{R} \geq 1$ .

The fractional saturation for an $n$ -subunit enzyme:

Y = \frac{L \cdot c ( 1 + c [ S ] / K _{R} ) ^{n - 1} [ S ] / K _{R} + ( 1 + [ S ] / K _{R} ) ^{n - 1} [ S ] / K _{R}}{L ( 1 + c [ S ] / K _{R} ) ^{n} + ( 1 + [ S ] / K _{R} ) ^{n}}

When $L ≫ 1$ (T state strongly favoured) and $c ≫ 1$ (T has much lower affinity), the curve is sigmoidal: at low $[S]$ , the enzyme is predominantly in the low-affinity T state; as $[S]$ increases, ligand binding shifts the equilibrium toward the high-affinity R state, creating the characteristic S-shaped response.

K-systems (where the effector changes $K_{0.5}$ but not $V_{ma x}$ ) and V-systems (where the effector changes $V_{ma x}$ but not $K_{0.5}$ ) are distinguished by whether the allosteric transition affects substrate binding affinity or catalytic rate. Most allosteric enzymes are K-systems.

Exercises Intermediate+

Exercise 3 (medium, short-answer).

Derive the rate equation for competitive inhibition and show that the apparent $K_{M}$ increases by the factor $(1 + [I] / K_{I})$ while $V_{ma x}$ is unchanged.

Hint

The mechanism adds $E + I ⇌ EI$ to the standard Michaelis-Menten scheme. Total enzyme is now $[E]_{T} = [E] + [E S] + [E I]$ . Apply the steady-state approximation to [ES] and the equilibrium approximation for EI.

Answer

Mechanism: $E + S ⇌ ES \to E + P$ , with $E + I ⇌ EI$ (inactive).

$[E I] = [E] [I] / K_{I}$ where $K_{I}$ is the dissociation constant for the EI complex.

Total enzyme: $[E]_{T} = [E] + [E S] + [E I] = [E] (1 + [I] / K_{I}) + [E S]$ .

Steady state: $[E S] = [E] [S] / K_{M}$ .

Substituting: $[E]_{T} = [E S] \cdot K_{M} / [S] \cdot (1 + [I] / K_{I}) + [E S] = [E S] (K_{M} (1 + [I] / K_{I}) / [S] + 1)$ .

[E S] = \frac{[ E ] _{T} [ S ]}{K _{M} ( 1 + [ I ] / K _{I} ) + [ S ]}

Rate: $v = k_{c a t} [E S] = \frac{V _{ma x} [ S ]}{K _{M}^{a pp} + [ S ]}$ where $K_{M}^{a pp} = K_{M} (1 + [I] / K_{I})$ and $V_{ma x} = k_{c a t} [E]_{T}$ is unchanged.

Exercise 5 (medium, short-answer).

Explain how the MWC model accounts for the effect of a heterotropic allosteric activator on the substrate saturation curve of an allosteric enzyme.

Hint

An allosteric activator binds preferentially to the R state. How does this change the allosteric constant $L$ ?

Answer

An allosteric activator binds preferentially to the R state, stabilising it relative to the T state. In the MWC model, this effectively decreases the allosteric constant $L = [T_{0}] / [R_{0}]$ — the R state is more populated in the absence of substrate. With a lower effective $L$ , the enzyme begins its substrate saturation curve at a higher baseline affinity (more R-state character), making the curve less sigmoidal and more hyperbolic. The apparent $K_{0.5}$ decreases (higher apparent affinity) and the Hill coefficient decreases (reduced cooperativity). At saturating activator, the enzyme is fully in the R state and shows Michaelis-Menten kinetics. Conversely, an allosteric inhibitor binds preferentially to the T state, increasing $L$ and making the curve more sigmoidal with a higher $K_{0.5}$ .

Exercise 6 (hard, short-answer).

Derive the Hill equation from a simplified binding model where an enzyme with $n$ identical subunits is either fully unliganded ( $E$ ) or fully saturated ( $E S_{n}$ ), with no partially liganded intermediates. State the limitations of this assumption.

Hint

Write the equilibrium between $E$ and $E S_{n}$ : $K = [E] [S]^{n} / [E S_{n}]$ . Express the fractional saturation $Y$ in terms of $[S]$ , $K$ , and $n$ .

Answer

Model: $E + n S ⇌ E S_{n}$ , with overall dissociation constant $K_{d} = [E] [S]^{n} / [E S_{n}]$ .

Total enzyme: $[E]_{T} = [E] + [E S_{n}]$ .

Fractional saturation: $Y = [E S_{n}] / [E]_{T} = [E S_{n}] / ([E] + [E S_{n}])$ .

From the equilibrium: $[E S_{n}] = [E] [S]^{n} / K_{d}$ .

Y = \frac{[ E ] [ S ] ^{n} / K _{d}}{[ E ] + [ E ] [ S ] ^{n} / K _{d}} = \frac{[ S ] ^{n} / K _{d}}{1 + [ S ] ^{n} / K _{d}} = \frac{[ S ] ^{n}}{K _{d} + [ S ] ^{n}}

Setting $K_{d} = K_{0.5}^{n}$ and $n = n_{H}$ , this is the Hill equation: $Y = [S]^{n_{H}} / (K_{0.5}^{n_{H}} + [S]^{n_{H}})$ .

Limitations. The assumption that no partially liganded intermediates exist is physically unrealistic for any real protein. In reality, subunits bind substrate sequentially, and the Hill model glosses over the intermediate species. The Hill coefficient $n_{H}$ obtained from fitting experimental data is therefore always less than the actual number of binding sites $n$ , and the Hill equation provides no structural information about the binding mechanism. It is a purely empirical descriptor of cooperativity.

Exercise 7 (hard, short-answer).

Compare the information content of a Hill plot with that of an Adair equation fit for a tetrameric cooperative enzyme. Why does the Adair treatment provide a more complete description of cooperativity?

Hint

The Adair equation uses stepwise binding constants $K_{1}, K_{2}, K_{3}, K_{4}$ for a tetramer. How many independent parameters does each method use, and what mechanistic information do they encode?

Answer

The Hill equation uses two parameters ( $V_{ma x}$ and $n_{H}$ , plus $K_{0.5}$ ) to describe the entire saturation curve. The Hill coefficient $n_{H}$ is a single scalar that quantifies the overall degree of cooperativity but says nothing about whether cooperativity is uniform across the binding process or concentrated in particular steps.

The Adair equation for a tetramer uses four stepwise macroscopic association constants $κ_{1}, κ_{2}, κ_{3}, κ_{4}$ (or their products, the Adair constants $A_{1} = κ_{1}$ , $A_{2} = κ_{1} κ_{2}$ , $A_{3} = κ_{1} κ_{2} κ_{3}$ , $A_{4} = κ_{1} κ_{2} κ_{3} κ_{4}$ ):

Y = \frac{A _{1} [ S ] + 2 A _{2} [ S ] ^{2} + 3 A _{3} [ S ] ^{3} + 4 A _{4} [ S ] ^{4}}{4 ( 1 + A _{1} [ S ] + A _{2} [ S ] ^{2} + A _{3} [ S ] ^{3} + A _{4} [ S ] ^{4} )}

The Adair treatment tracks how the apparent affinity changes with each successive binding event. If $κ_{1} < κ_{2} < κ_{3} < κ_{4}$ , cooperativity increases progressively. If $κ_{1} < κ_{2} > κ_{3}$ , the pattern is more complex — positive cooperativity for the first two binding events followed by a decrease. The Hill coefficient collapses all this information into a single number, losing the step-by-step detail. For drug design and understanding allosteric mechanism, the Adair constants are far more informative.

Inhibition in drug design and irreversible inhibition Master

Reversible inhibition (competitive, uncompetitive, mixed) is the kinetic framework for understanding most drug-enzyme interactions. But the full pharmacological landscape includes irreversible inhibitors, slow-binding inhibitors, and tight-binding inhibitors whose kinetics require extensions beyond the standard rapid-equilibrium framework.

Mechanism-based (suicide) inhibitors. These substrates are processed by the enzyme's normal catalytic machinery but generate a reactive intermediate that covalently modifies the active site, irreversibly inactivating the enzyme. The key distinction from simple irreversible inhibitors: mechanism-based inhibitors require catalytic turnover to generate the inactivating species, which means they are selective for the target enzyme and unlikely to react with off-target proteins.

Clavulanic acid is a mechanism-based inhibitor of beta-lactamases, the bacterial enzymes that hydrolyse and inactivate penicillin antibiotics. Clavulanic acid enters the beta-lactamase active site and is processed by the serine nucleophile (the same Ser that hydrolyses penicillin). The acyl-enzyme intermediate undergoes a rearrangement that generates a reactive conjugated imine, which alkylates a second active-site residue. The enzyme is permanently inactivated. Amoxicillin-clavulanate (Augmentin) exploits this: clavulanate sacrifices the beta-lactamase, allowing amoxicillin to reach its target. This is a nontrivial example of transition-state chemistry applied to antibiotic design.

Slow-binding and tight-binding inhibitors. The standard inhibition equations assume that the inhibitor binds rapidly and the EI complex reaches equilibrium on a timescale much faster than the steady-state rate measurement. When inhibitor binding is slow (conformational change after initial binding) or tight ( $K_{I}$ comparable to $[E]_{T}$ ), the standard equations break down.

For tight-binding inhibitors ( $K_{I} \leq 10 \times [E]_{T}$ ), the Morrison equation replaces the standard Cheng-Prusoff relationship. The rate depends on total enzyme concentration because a significant fraction of inhibitor is bound:

v = v_{0} (1 - \frac{([ E ] _{T} + [ I ] _{T} + K _{I}^{a pp} ) - ([ E ] _{T} + [ I ] _{T} + K _{I}^{a pp} ) ^{2} - 4 [ E ] _{T} [ I ] _{T}}{2 [ E ] _{T}})

where $v_{0}$ is the uninhibited rate and $K_{I}^{a pp}$ is the apparent inhibitor constant. The Morrison equation is essential for determining $K_{I}$ values in the nanomolar to picomolar range, where the standard assumption $[I]_{f r ee} \approx [I]_{t o t a l}$ fails catastrophously.

Slow-binding inhibitors exhibit time-dependent inhibition: the initial rate decreases gradually over seconds to minutes as the EI complex slowly isomerises to a more tightly bound EI* complex. The two-step mechanism $E + I ⇌ EI ⇌ E I^{*}$ produces progress curves that are exponential rather than linear. Methotrexate, a dihydrofolate reductase inhibitor used in cancer chemotherapy, is a classic slow-binding inhibitor with $K_{I}^{*} \approx 1 0^{- 11} M$ for the final EI* complex.

Koshland-Nemethy-Filmer sequential model vs MWC concerted model Master

The MWC model and the KNF model offer fundamentally different physical pictures of how cooperativity arises in multi-subunit enzymes. Both were published in the mid-1960s and both remain in use, because each captures aspects of allosteric behaviour that the other does not.

MWC concerted model (Monod, Wyman, Changeux 1965). The enzyme exists in two global conformational states (T and R). All $n$ subunits within a single enzyme molecule share the same conformation — hybrid T/R oligomers are excluded. Ligand binding shifts the T/R equilibrium by preferentially stabilising the R state. The cooperativity arises because the first ligand binding event shifts the entire oligomer from T to R, simultaneously increasing the affinity of all remaining empty sites.

The MWC model cannot describe negative cooperativity. Because the conformational change is concerted (all-or-none), every binding event pulls in the same direction: toward the R state. The model predicts that the Hill coefficient is always between 1 and $n$ , with no possibility of $n_{H} < 1$ .

KNF sequential model (Koshland, Nemethy, Filmer 1966). Each subunit undergoes a local conformational change upon ligand binding (induced fit). The conformational change in one subunit alters the interfaces with neighbouring subunits, changing their affinity. Hybrid conformations are allowed — a tetramer might have two subunits in the "bound" conformation and two in the "unbound" conformation simultaneously.

The KNF model can describe both positive cooperativity (the induced change increases neighbour affinity) and negative cooperativity (the induced change decreases neighbour affinity). Negative cooperativity arises when the conformational change in one subunit distorts the interface in a way that makes the adjacent subunit less able to bind ligand. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) shows negative cooperativity for NAD $^{+}$ binding: the first two NAD $^{+}$ molecules bind with high affinity, but the conformational changes induced by their binding reduce the affinity of the remaining two sites. This behaviour is impossible under the MWC framework and requires a sequential model.

Quantitative comparison. For hemoglobin, the MWC model fits the oxygen saturation data well with four parameters ( $L$ , $c$ , $K_{R}$ , $n = 4$ ). The KNF model requires more parameters (the interaction energies between subunit pairs in each conformational state) but can accommodate asymmetric behaviour such as the Bohr effect's differential impact on the alpha and beta subunits. Perutz's stereochemical mechanism for hemoglobin — in which the T-to-R transition involves a rotation of one alpha-beta dimer relative to the other by approximately 15 degrees, breaking specific salt bridges — is more naturally described by the MWC framework because the transition is quasi-concerted, but the detailed pathway involves sequential breaking of intersubunit contacts that is better captured by a sequential model.

Modern allosteric theory, developed by Wyman, Weber, and others, treats allostery as a statistical-mechanical ensemble problem. The enzyme samples a large number of microstates (conformations, ligand occupancies), and ligand binding reshapes the ensemble distribution. This framework subsumes both MWC and KNF as special cases and can be applied to any protein, regardless of whether it has the classic symmetric oligomeric architecture assumed by the original models.

Pre-steady-state kinetics and isotope effects Master

Steady-state kinetics, the focus of the intermediate tier, treats the enzyme as a black box that converts substrate to product with defined $K_{M}$ and $k_{c a t}$ . Pre-steady-state kinetics opens the black box by measuring individual rate constants for each step in the catalytic mechanism, using rapid-mixing techniques (stopped-flow, quenched-flow) that operate on the millisecond to microsecond timescale.

Burst kinetics. When an enzyme with a covalent intermediate (e.g., a serine protease) is mixed with substrate in a stopped-flow apparatus, the product concentration shows an initial burst followed by a slower linear phase. The burst amplitude equals the total enzyme concentration $[E]_{T}$ , because every enzyme molecule rapidly forms the acyl-enzyme intermediate and releases the first product. The subsequent linear phase corresponds to the rate-limiting deacylation step.

For chymotrypsin hydrolysing $p$ -nitrophenyl acetate at pH 7, the burst amplitude confirms that the acylation step ( $k_{2} \approx 1 0^{3} s^{- 1}$ ) is much faster than the deacylation step ( $k_{3} \approx 1 s^{- 1}$ ). The steady-state $k_{c a t}$ is dominated by the slower step: $k_{c a t} \approx k_{3} = 1 s^{- 1}$ . Without pre-steady-state data, the individual rate constants would be inaccessible.

Kinetic isotope effects. Replacing an atom in the substrate with a heavier isotope changes the rate of the reaction if that atom's bond is broken or formed in the rate-determining step. Primary kinetic isotope effects (KIEs) arise from the difference in zero-point vibrational energy between the light and heavy isotopes.

For C-H bond cleavage, replacing H with D gives a maximum primary KIE of $k_{H} / k_{D} \approx 7$ at room temperature when the C-H(D) bond is broken in the rate-determining step. Smaller observed values ( $k_{H} / k_{D} \approx 1.5$ – $3$ ) indicate that the C-H cleavage is partially rate-determining, or that the transition state is early (little C-H bond breaking). A KIE near 1.0 means C-H cleavage is not rate-determining.

The alcohol dehydrogenase mechanism was elucidated using deuterium and tritium isotope effects. The primary KIE of $k_{H} / k_{D} \approx 3.5$ for ethanol oxidation confirmed that hydride transfer from the substrate to NAD $^{+}$ is partially rate-determining. The pre-steady-state burst kinetics showed that NADH release, not hydride transfer, is the rate-limiting step at high [S], accounting for why the observed KIE is less than the intrinsic value.

Transition-state analogue inhibitors as drug design tools. The quantitative link between catalytic rate enhancement and transition-state binding affinity, first articulated by Wolfenden, provides a direct strategy for inhibitor design: if the enzyme binds the transition state $1 0^{10}$ -fold more tightly than the substrate, then a stable molecule mimicking the transition state should bind with picomolar affinity.

Phosphinate and phosphonate inhibitors of metalloproteases exploit this principle. The tetrahedral phosphorus mimics the tetrahedral transition state of amide hydrolysis, with the two oxygen atoms serving as analogues of the oxyanion. The zinc ion in the active site coordinates the phosphonate oxygen, reproducing the transition-state geometry. Phosphoramidon, a natural product phosphonate, inhibits thermolysin with $K_{I} \approx 30 nM$ — far below the $K_{M}$ of typical peptide substrates ( $\sim mM$ ).

Renin inhibitors for antihypertensive therapy were designed using the transition-state analogue approach. The transition state for the renin-catalysed hydrolysis of angiotensinogen has a tetrahedral carbon at the scissile bond. Replacing this carbon with a statine residue $[- CH (OH) C H_{2} CO -]$ mimics the tetrahedral geometry. Aliskiren, the first orally active direct renin inhibitor approved for hypertension (2007), uses a nonpeptidic scaffold that positions hydroxyl and amine groups to mimic the transition state, achieving $K_{I} \approx 0.6 nM$ .

Connections Master

Enzyme mechanism 15.14.01. The Michaelis-Menten framework derived in the prerequisite unit is the base case that this unit extends. Every inhibition type and allosteric model reduces to standard Michaelis-Menten when the inhibitor is removed or the allosteric constant is set to the simple limit ( $L = 0$ , no cooperativity). The steady-state approximation and the rate-law derivation techniques carry forward directly.
Chemical kinetics 14.08.01. The inhibition rate equations are applications of the general rate-law formalism: writing mechanisms, applying steady-state approximations, and extracting observable rate laws. The pre-steady-state burst kinetics analysis is an extension of the relaxation-method techniques from chemical kinetics.
Cellular respiration — glycolysis and TCA cycle 17.04.01. Phosphofructokinase-1 (PFK-1), the committed step of glycolysis, is the textbook K-system allosteric enzyme. Its sigmoidal fructose-6-phosphate kinetics, Hill coefficient $n_{H} \approx 1.8$ , activation by ADP and fructose-2,6-bisphosphate, and inhibition by ATP and citrate are direct applications of the allosteric models developed here. Understanding PFK-1 regulation is impossible without the MWC framework.
Pharmacology and drug design. Most pharmaceutical enzyme inhibitors are competitive (statins, sulfonamides, ACE inhibitors), but mechanism-based inhibitors (clavulanate, aspirin) and slow-binding tight inhibitors (methotrexate, allopurinol) are clinically essential. The inhibition-type classification developed here determines dosing strategy: competitive inhibitors can be overcome by high substrate (requiring higher drug doses), while irreversible and tight-binding inhibitors remain effective at lower doses.
Hemoglobin and oxygen transport. Hemoglobin is the paradigmatic cooperative protein. The MWC model was developed to explain its oxygen-binding behaviour. The Bohr effect (pH-dependent oxygen affinity), 2,3-BPG modulation, and fetal hemoglobin adaptation are all quantified using the MWC framework and Hill coefficients from this unit.
Protein engineering and directed evolution. Engineering allosteric regulation into enzymes requires understanding the T/R conformational equilibrium and its coupling to substrate binding. The MWC parameters $L$ and $c$ provide quantitative targets for mutagenesis: mutations that stabilise the T state increase $L$ and shift the curve toward more sigmoidal behaviour, while mutations that destabilise T decrease $L$ and make the enzyme more Michaelis-Menten-like.

Historical notes Master

The study of enzyme inhibition began with the observation that certain substances slow enzyme-catalysed reactions. Michaelis and Menten 1913 noted that their invertase kinetics were affected by the presence of other sugars, but the first systematic kinetic treatment of inhibition is due to Lineweaver and Burk 1934, who showed that competitive and noncompetitive inhibition produce distinct patterns on the double-reciprocal plot. Their linearisation method made it possible to classify inhibitors from experimental data without requiring nonlinear regression — a decisive advantage in the era before digital computers.

Eadie 1942 and Hofstee 1959 independently proposed the $v$ vs $v / [S]$ plot as a statistically superior alternative, and Hanes 1932 introduced the $[S] / v$ vs $[S]$ linearization. The debate over which linearization to use persisted for decades and was ultimately rendered moot by the availability of nonlinear regression software in the 1980s, though the Lineweaver-Burk plot remains the standard diagnostic tool for inhibition classification.

The Hill equation was introduced by Archibald Hill in 1910 to describe the cooperative binding of oxygen to hemoglobin. Hill's original paper treated the cooperativity as arising from aggregation of multiple hemoglobin molecules rather than multiple subunits within a single molecule — the subunit structure of hemoglobin was not established until Svedberg's ultracentrifugation studies in the 1920s and Perutz's X-ray structures in the 1960s. The Hill coefficient has persisted as the standard metric of cooperativity despite being an empirical parameter with no direct mechanistic interpretation.

The Monod-Wyman-Changeux model was published in 1965 in the Journal of Molecular Biology, followed one year later by the Koshland-Nemethy-Filmer model in Biochemistry. The two models were developed independently and represent fundamentally different physical pictures of cooperativity. The MWC model assumes concerted conformational change (all subunits switch simultaneously), while the KNF model assumes sequential induced-fit changes propagating through the oligomer. The competition between these models drove the field of allosteric regulation for a decade, with hemoglobin data fitting the MWC model better and several allosteric enzymes (showing negative cooperativity) requiring the KNF framework.

The pre-steady-state kinetic techniques were pioneered by Britton Chance in the 1940s using a custom-built stopped-flow apparatus to measure the formation and breakdown of the enzyme-substrate complex of peroxidase. Chance's work was the first direct observation of the ES complex predicted by Michaelis and Menten, and it opened the field of single-turnover kinetics that allows measurement of individual rate constants within the catalytic mechanism.

The application of kinetic isotope effects to enzyme mechanism was developed independently by Westheimer, Rose, and others in the 1960s. Rose's use of tritium isotope effects to determine the stereochemistry of NAD $^{+}$ -dependent hydride transfer (1970) established the A-face/B-face selectivity that is now a standard tool for classifying dehydrogenase mechanisms. The combination of pre-steady-state kinetics and isotope effects remains the most powerful approach for dissecting multi-step enzyme mechanisms.

Bibliography Master

@article{Hill1910,
  author = {Hill, Archibald V.},
  title = {The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves},
  journal = {J. Physiol.},
  volume = {40},
  pages = {iv--vii},
  year = {1910},
}

@article{LineweaverBurk1934,
  author = {Lineweaver, Hans and Burk, Dean},
  title = {The Determination of Enzyme Dissociation Constants},
  journal = {J. Am. Chem. Soc.},
  volume = {56},
  pages = {658--666},
  year = {1934},
}

@article{MonodWymanChangeux1965,
  author = {Monod, Jacques and Wyman, Jeffries and Changeux, Jean-Pierre},
  title = {On the Nature of Allosteric Transitions: A Plausible Model},
  journal = {J. Mol. Biol.},
  volume = {12},
  pages = {88--118},
  year = {1965},
}

@article{KoshlandNemethyFilmer1966,
  author = {Koshland, Daniel E. and Nemethy, George and Filmer, David},
  title = {Comparison of Experimental Binding Data and Theoretical Models in Proteins Containing Subunits},
  journal = {Biochemistry},
  volume = {5},
  pages = {365--385},
  year = {1966},
}

@article{ChengPrusoff1973,
  author = {Cheng, Yung-Chi and Prusoff, William H.},
  title = {Relation between the inhibition constant ($K_I$) and the concentration of inhibitor which causes 50 per cent inhibition ($I_{50}$) of an enzymatic reaction},
  journal = {Biochem. Pharmacol.},
  volume = {22},
  pages = {3099--3108},
  year = {1973},
}

@article{Morrison1969,
  author = {Morrison, John F.},
  title = {Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors},
  journal = {Biochim. Biophys. Acta},
  volume = {185},
  pages = {269--286},
  year = {1969},
}

@book{Segel1993,
  author = {Segel, Irwin H.},
  title = {Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems},
  publisher = {Wiley},
  year = {1993},
}

@book{VoetVoet2016,
  author = {Voet, Donald and Voet, Judith G.},
  title = {Biochemistry},
  edition = {5th},
  publisher = {Wiley},
  year = {2016},
}

@book{Fersht1999,
  author = {Fersht, Alan},
  title = {Enzyme Structure and Mechanism},
  edition = {2nd},
  publisher = {W. H. Freeman},
  year = {1999},
}

@book{CookCleland2007,
  author = {Cook, Paul F. and Cleland, W. W.},
  title = {Enzyme Kinetics and Mechanism},
  publisher = {Garland Science},
  year = {2007},
}

@book{McMurry2019,
  author = {McMurry, John},
  title = {Organic Chemistry},
  edition = {10th},
  publisher = {Cengage},
  year = {2019},
}